WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130204
CAS#: 1467047-91-1
Description: SRS11-92 is an inhibitor of ferroptosis and was found to decrease cell death associated with frataxin knockdown in healthy human fibroblasts, which is indicative of the potential of SRS11-92 as a treatment for Friedreich ataxia.
Hodoodo Cat#: H130204
Name: SRS11-92
CAS#: 1467047-91-1
Chemical Formula: C21H27N3O2
Exact Mass: 353.21
Molecular Weight: 353.470
Elemental Analysis: C, 71.36; H, 7.70; N, 11.89; O, 9.05
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: SRS11-92; SRS 11-92; SRS-11-92; SRS11 92; SRS 11 92
IUPAC/Chemical Name: ethyl 5-(benzylamino)-6-(cyclohexylamino)nicotinate
InChi Key: WRUIDZKNUAHKTR-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H27N3O2/c1-2-26-21(25)17-13-19(22-14-16-9-5-3-6-10-16)20(23-15-17)24-18-11-7-4-8-12-18/h3,5-6,9-10,13,15,18,22H,2,4,7-8,11-12,14H2,1H3,(H,23,24)
SMILES Code: O=C(C1=CC(NCC2=CC=CC=C2)=C(NC3CCCCC3)N=C1)OCC
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Friedreich ataxia results in ataxia, sensory loss, and hypertrophic cardiomyopath, due to decreased expression of frataxin, which in turn, leads to mitochondrial dysfunction. Ferroptosis has been thought to play a role in the Friedreich ataxia, in that ferroptosis leads to iron-dependent cell death.
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 353.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Cotticelli MG, Xia S, Lin D, Lee T, Terrab L, Wipf P, Huryn DM, Wilson RB. Ferroptosis as a Novel Therapeutic Target for Friedreich's Ataxia. J Pharmacol Exp Ther. 2019 Apr;369(1):47-54. doi: 10.1124/jpet.118.252759. Epub 2019 Jan 11. PMID: 30635474.